Category: Company Updates

This category can only be viewed by members. To view this category, sign up by purchasing One Year Individual Subscription, One Year Individual Subscription (Digital), Two Year Individual Subscription, Two Year Individual Subscription (Digital), Three Year Individual Subscription, Three Year Individual Subscription (Digital), One Year Group Subscription, One Year Group Subscription (Digital), Two Year Group Subscription, Two Year Group Subscription (Digital), Three Year Group Subscription or Three Year Group Subscription (Digital).

Nektar Update (11-16-12)

Nektar’s stock has had a horrible two weeks despite announcing positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). Last week, potential FDA concerns with CV risk associated with opioid withdrawal in chronic use of opioid antagonists became an investor issue[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Anthera Update (11-02-12)

Anthera’s stock is up since the last Issue as they have had two encouraging announcements. The most important was this week when they announced that an abstract from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibimod in systemic lupus patients has been accepted as a Late-Breaking poster presentation at the 2012 Annual[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (10-19-12)

Celgene’s stock is down since the last Issue as it also corrected this Friday. This week, additional information became available on the FDA’s website regarding the cancellation of the November 8th ODAC meeting originally scheduled to discuss pomalidomide. The website now specifically says that ”the issues for which the FDA was seeking the scientific input of the[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (11-16-12)

Celgene’s stock is up since the last Issue on good news. The company announced that Abraxane has achieved overall survival (OS) is Phase III trial treating metastatic pancreatic cancer patients.  CELG did not provide any exact results as they plan to present the data at an upcoming scientific meeting. We do know that the company designed[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Aastrom Update (11-02-12)

Aastrom has announced that cell therapy regulatory and development expert Joyce L. Frey-Vasconcells, Ph.D. has been appointed to the company’s Scientific Advisory Board (SAB). Dr. Frey-Vasconcells is considered one of the foremost regulatory experts on cell therapies, tissues and gene therapies.  Dr. Frey-Vasconcells is founder and president of Frey-Vasconcells Consulting LLC and previously served as a[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Alkermes Update (11-02-12)

Alkermes reported financial results for its second quarter of fiscal 2013, which ended Sept. 30, 2012, and the company provided improved financial expectations for its fiscal year 2013. Total revenues for the second quarter of fiscal 2013 increased more than 72% to $124.0 million, compared to the same period in fiscal 2012, which was attributable[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Novavax Update (11-02-12)

NovaVax announced that it has raised a total of $27 million through the sale of 12,285,321 shares of its common stock to RA Capital Management, Camber Capital Management and Ayer Capital Management at a price of $2.18 per share. The shares were offered under an effective shelf registration statement previously filed with the Securities and[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by